Foley Hoag advised Vesica Health, a U.S.-based precision diagnostics company, in its sale to Photocure ASA (OSE: PHO), a leader in bladder cancer diagnostics. The $30.5 million cash and stock transaction includes milestone-based payments tied to future reimbursement achievements and was announced and completed on June 4, 2026.
Vesica Health is advancing AssureMDx, a urine-based molecular test for the early detection of bladder cancer. The transaction is expected to expand Photocure’s position across the bladder cancer care continuum and enhance its noninvasive diagnostic capabilities.
The Foley Hoag team advising Vesica Health included Jeffrey Quillen, Shane Safer, Sarah Kelley and Nathan Wright.
